A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-R)
I1F-MC-RHCR - ClinicalTrials.gov - NCT03573323
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Plaque PsoriasisWhat the trial is testing?
Guselkumab, IxekizumabCould I receive a Placebo?
YesEnrollment Goal
1027Trial Dates
Nov 9, 2018 - Jan 8, 2020How long will I be in the trial?
The study will last about 24 weeks and may include up to 12 visits (follow up includes up to 3 visits).Trial Phase
IVLilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo